000 03384nam a22003855i 4500
001 309970
003 MX-SnUAN
005 20160429160334.0
007 cr nn 008mamaa
008 150903s2006 sz | o |||| 0|eng d
020 _a9783764374389
_99783764374389
024 7 _a10.1007/3764374381
_2doi
035 _avtls000362763
039 9 _a201509030453
_bVLOAD
_c201404121600
_dVLOAD
_c201404091337
_dVLOAD
_y201402211057
_zstaff
040 _aMX-SnUAN
_bspa
_cMX-SnUAN
_erda
050 4 _aQR180-189.5
100 1 _aWeinberg, Jeffrey M.
_eeditor.
_9350061
245 1 0 _aTNF-alpha Inhibitors /
_cedited by Jeffrey M. Weinberg, Robin Buchholz.
264 1 _aBasel :
_bBirkhäuser Basel,
_c2006.
300 _aIx, 133 páginas 10 ilustraciones
_brecurso en línea.
336 _atexto
_btxt
_2rdacontent
337 _acomputadora
_bc
_2rdamedia
338 _arecurso en línea
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
_2rda
490 0 _aMilestones in Drug Therapy
500 _aSpringer eBooks
505 0 _ato TNF/pathophysiology of TNF -- History of development of TNF inhibitors -- Pharmacology of TNF inhibitors -- Etanercept in rheumatology -- Etanercept in dermatology and off-label use -- Infliximab in rheumatology -- Infliximab in dermatology, gastroenterology, and off-label use -- Adalimumab in rheumatology -- Adalimumab in dermatology -- A review of the safety of the tumor necrosis inhibitors infliximab, etanercept, and adalimumab.
520 _aOver the last decade, the advent of biologic agents has greatly revolutionized therapeutic medicine in the management of chronic inflammatory diseases, such as rheumatoid arthritis, Crohn’s disease, and psoriasis. Elucidation of the complex web of cytokine network and the roles of these cytokines in the pathogenesis of inflammatory disorders provided one of the key catalysts for the advancement of targeted biologic therapy in autoimmune and inflammatory diseases. TNF-alpha is known to play a crucial role in the pathogenesis of many chronic inflammatory diseases. Elevated levels of TNF-alpha have been demonstrated in Crohn’s disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, suggesting a role for TNF-alpha in their pathogenesis. Although TNF-alpha plays a critical role in the activation of innate and acquired immune responses, the persistence of the immune response and inappropriate production of TNF-alpha can produce pathological changes resulting from chronic inflammation and tissue damage. This volume provides a comprehensive overview of the development, pharmacology, efficacy, and safety of the currently available TNF-alpha inhibitors – etanercept, infliximab, and adalimumab. The most recent preclinical and clinical data is presented on this topic, which should be of interest to the preclinical researcher, the clinician, and the patient who wants to learn more about these therapies.
590 _aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700 1 _aBuchholz, Robin.
_eeditor.
_9350502
710 2 _aSpringerLink (Servicio en línea)
_9299170
776 0 8 _iEdición impresa:
_z9783764372484
856 4 0 _uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/3-7643-7438-1
_zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942 _c14
999 _c309970
_d309970